Day One Biopharmaceuticals, Inc. Common Stock
DAWNDay One Biopharmaceuticals, Inc. (DAWN) is a clinical-stage biotechnology company focused on developing innovative therapies for rare and severe neurological disorders. The company leverages its proprietary gene therapy platform to address unmet medical needs, primarily targeting pediatric patients with neurodegenerative and neurogenetic conditions.
Company News
Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics for up to $285 million, expanding its oncology pipeline with a focus on developing antibody-drug conjugates targeting cancers, particularly in pediatric and triple-negative breast cancer treatments.
Day One Biopharmaceuticals announced it will acquire Mersana Therapeutics for approximately $129 million, expanding its oncology portfolio with the antibody-drug conjugate emiltatug ledadotin (Emi-Le), which shows early anti-tumor activity in adenoid cystic carcinoma treatment.
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
The clinical-stage biotech released early trial news regarding its lead therapy candidate.
